Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data

• DOI: 10.1111/cts.13761
• Publication Date: 2024-03-13T07:09:57Z
• Authors: Bianca Kruger; Delva Shamley; Nyarai Desiree Soko; Collet Dandara
• Keywords: 0301 basic medicine; Polymorphism, Genetic; Breast Neoplasms; RM1-950; Tamoxifen; 03 medical and health sciences; Cytochrome P-450 CYP2D6; Pharmacogenetics; Humans; Female; Therapeutics. Pharmacology; Public aspects of medicine; RA1-1270; Systemic Reviews

Abstract Tamoxifen, a selective estrogen receptor modulator, is used to treat hormone receptor‐positive breast cancer. Tamoxifen acts as prodrug, with its primary therapeutic effect mediated by principal metabolite, endoxifen. However, tamoxifen has complex pharmacokinetics involving several drug‐metabolizing enzymes and transporters influencing disposition. Genes encoding involved in disposition exhibit genetic polymorphisms which vary widely across world populations. This review highlights the lack of data on pharmacogenetics among African Gaps are described this study purpose that future research can address dearth cancer patients. Initiatives such Pharmacogenomics Network (APN) crucial promoting comprehensive studies pinpoint important variants pharmacogenes could be reduce toxicity improve efficacy.